Sanofi (SNY) Gains from Investment Securities (2010 - 2026)

Sanofi has disclosed Gains from Investment Securities across 17 years of filings, most recently posting $41.0 million for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $41.0 million, up 532.83% year-over-year; the trailing twelve-month figure through Mar 2026 was -$275.7 million (down 29.83% YoY), and the FY2025 annual result was -$409.7 million, down 4.77% from the prior year.
• Gains from Investment Securities came in at $41.0 million for Q1 2026 at Sanofi, up from -$121.1 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $100.1 million in Q4 2023 to a low of -$385.2 million in Q2 2022.
• The 5-year median for Gains from Investment Securities is -$9.5 million (2025), against an average of -$48.0 million.
• Across the five-year window, Gains from Investment Securities soared 717.31% in 2023 and plunged 1456.83% in 2025, its largest moves.
• Sanofi's Gains from Investment Securities stood at $12.2 million in 2022, then jumped by 717.31% to $100.1 million in 2023, then plunged by 202.52% to -$102.6 million in 2024, then retreated by 18.01% to -$121.1 million in 2025, then jumped by 133.85% to $41.0 million in 2026.
• The last three Gains from Investment Securities figures came in at $41.0 million (Q1 2026), -$121.1 million (Q4 2025), and -$136.8 million (Q3 2025), per Business Quant data.